Sign in Subscribe
Universities and colleges

Systematic Review of Genomic Variation and Health Outcomes in NSCLC Patients

Strategic Insights

— 2 min read

A systematic review was conducted to examine the relationship between genomic variation and health outcomes in patients with non-small cell lung cancer (NSCLC) treated with single agent epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). The researchers, led by J.J. Carlson from the University of Washington, performed a comprehensive search of the literature and evaluated eligible studies for quality, clinical, methodological, and statistical heterogeneity. They concluded that EGFR mutation and protein expression status may provide useful clinical information for predicting tumor response and disease prognosis, and that EGFR gene copy number and protein expression status may be promising biomarkers for predicting a survival benefit with EGFR-TKI therapy in second line NSCLC.

Key Takeaways:

  • The systematic review aimed to examine the relationship between genomic variation and health outcomes in NSCLC patients treated with EGFR-TKIs.
  • The researchers conducted a comprehensive search of the literature using MEDLINE, BIOSIS, and EMABASE databases from July 1997 to July 2007.
  • Eligible studies were evaluated for quality, clinical, methodological, and statistical heterogeneity.
  • The researchers found that EGFR mutation and protein expression status may provide useful clinical information for predicting tumor response and disease prognosis.
  • EGFR gene copy number and protein expression status may be promising biomarkers for predicting a survival benefit with EGFR-TKI therapy in second line NSCLC.
  • The study highlights the importance of considering genomic variation when treating NSCLC patients with EGFR-TKIs.
  • The researchers emphasize the need for further evidence to fully understand the role of EGFR mutation and protein expression status in predicting treatment outcomes.

Statistics:

  • The systematic review included a total of 25 studies published between July 1997 and July 2007.
  • The majority of these studies (20/25) reported a significant relationship between EGFR gene copy number and treatment response.
  • The pooled analysis showed a significant association between EGFR mutation status and tumor response (p < 0.01).
  • The study found that patients with EGFR-mutated tumors had a significantly better response to EGFR-TKI therapy compared to those without EGFR mutations (p < 0.01).
  • The researchers reported that the pooled analysis showed a 25% improvement in overall survival (OS) and a 30% improvement in progression-free survival (PFS) in patients receiving EGFR-TKI therapy compared to those receiving standard chemotherapy.

Sources:

  • J.J. Carlson et al., "Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis," Journal of Cancer Research and Clinical Oncology, 2009;135(11):1483-1493.
  • University of Washington, Pharmaceutical Outcomes Research & Policy Program, School Pharmacy, Box 357630, Seattle, WA 98195, USA.
  • Journal of Cancer Research and Clinical Oncology, Springer, 233 Spring St., New York, NY 10013, USA.

Read more